成人癫痫药物治疗研究进展

doi:10.12092/j.issn.1009-2501.2026.02.001

摘要/Abstract

摘要：

癫痫是常见的慢性中枢神经系统疾病，70%的患者可通过抗癫痫发作药物（antiseizure medications，ASMs）治疗控制。成人癫痫药物治疗领域近年来取得了显著进展，新型抗癫痫药物不断涌现。育龄期女性及老年癫痫患者等特殊人群得到了进一步重视。本文综述了成人癫痫药物治疗的研究进展，为成人癫痫患者提供更加个体化、有效的药物治疗方案提供参考。

关键词: 成人, 癫痫, 药物治疗

Abstract:

Epilepsy is a kind of common chronic nervous system disease, with approximately 70% of patients achieving seizure free through antiseizure medications (ASMs). Recent years have witnessed significant advancements in the pharmacological treatment of adult epilepsy, marked by the emergence of novel antiepileptic drugs. Special populations, including women of childbearing age and older adults with epilepsy, have garnered increased clinical attention. This review summarizes recent research progress in drug therapy for adult epilepsy, aiming to provide evidence-based references for more individualized and effective treatment strategies.

Key words: adult, epilepsy, pharmacotherapy

中图分类号:

R742.1

陈怡伶, 朱国行. 成人癫痫药物治疗研究进展[J]. 中国临床药理学与治疗学, 2026, 31(2): 146-153.

Yiling CHEN, Guoxing ZHU. Advances in pharmacotherapy for adult epilepsy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(2): 146-153.

图/表 1

参考文献 57

1	中国抗癫痫协会. 临床诊疗指南: 癫痫分册(2023修订版)[M]. 北京: 人民卫生出版社, 2023.
2	Sen A, Jette N, Husain M, et al. Epilepsy in older people[J]. The Lancet, 2020, 395 (10225): 735- 748. doi: 10.1016/S0140-6736(19)33064-8
3	Kanner AM, Bicchi MM. Antiseizure medications for adults with epilepsy: a review[J]. JAMA, 2022, 327 (13): 1269. doi: 10.1001/jama.2022.3880
4	Abou-Khalil BW. Update on antiseizure medications 2022[J]. Continuum (Minneap Minn), 2022, 28 (2): 500- 535. doi: 10.1212/CON.0000000000001104
5	Meador KJ, Loring DW, Ray PG, et al. Differential cognitive and behavioral effects of carbamazepine and lamotrigine[J]. Neurology, 2001, 56 (9): 1177- 1182. doi: 10.1212/WNL.56.9.1177
6	Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults[J]. New Engl J Med, 1992, 327 (11): 765- 771. doi: 10.1056/NEJM199209103271104
7	Elosua-Bayes I, Abraira L, Fonseca E, et al. Trends in antiseizure medication prescription in Idiopathic generalized epilepsy over the last 10 years[J]. Epil Beh, 2025, 163, 110158. doi: 10.1016/j.yebeh.2024.110158
8	Abou-Khalil BW. Update on antiseizure medications 2025[J]. Continuum (Minneap Minn), 2025, 31 (1): 125- 164. doi: 10.1212/cont.0000000000001521
9	Azar NJ, Wright AT, Wang L, et al. Generalized tonic-clonic seizures after acute oxcarbazepine withdrawal[J]. Neurol, 2008, 70 (22_part_2): 2187- 2188.
10	Brown JC, Broadway JL. Lamotrigine-associated progressive dysphasia and cognitive dysfunction[J]. OBM Neurobiol, 2020, 5 (2): 91. doi: 10.21926/obm.neurobiol.2102091
11	Beuchat I, Novy J, Rossetti AO. Newer antiepileptic drugs for status epilepticus in adults: what's the evidence ?[J]. CNS Drugs, 2018, 32 (3): 259- 267. doi: 10.1007/s40263-018-0509-5
12	Baulac M, Brodie MJ, Patten A, et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial[J]. Lancet Neurol, 2012, 11 (7): 579- 588. doi: 10.1016/S1474-4422(12)70105-9
13	Vossler DG, Knake S, O'Brien TJ, et al. Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial[J]. J Neurol Neurosurg Psychiatry, 2020, 91 (10): 1067- 1075. doi: 10.1136/jnnp-2020-323524
14	Strzelczyk A, Knake S, Kälviäinen R, et al. Perampanel for treatment of status epilepticus in Austria, Finland, Germany, and Spain[J]. Acta Neurologica Scandinavica, 2019, 139 (4): 369- 376. doi: 10.1111/ane.13061
15	Yamamoto T, Lim SC, Ninomiya H, et al. Long-term efficacy and safety of perampanel monotherapy in patients with newly diagnosed or currently untreated recurrent focal-onset seizures: results from the open-label extension phase of FREEDOM (Study 342)[J]. Epil Res, 2025, 210, 107494. doi: 10.1016/j.eplepsyres.2024.107494
16	Aicua-Rapun I, André P, Rossetti AO, et al. Intravenous brivaracetam in status epilepticus: correlation between loading dose, plasma levels and clinical response[J]. Epil Res, 2019, 149, 88- 91. doi: 10.1016/j.eplepsyres.2018.12.001
17	O'Brien TJ, Borghs S, He Q (Jane), et al. Long‐term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: an up to 11‐year, open‐label, follow‐up trial[J]. Epilepsia, 2020, 61 (4): 636- 646. doi: 10.1111/epi.16484
18	Ranganathan LN, Kulkarni G, Kakkad A, et al. First clinical post-approval, observational study to assess clinical safety and effectiveness of brivaracetam sustained-release formulation in real-life settings of India: BEAM study[J]. Seizure, 2025, 125, 132- 139. doi: 10.1016/j.seizure.2025.01.011
19	Bakas T, Van Nieuwenhuijzen PS, Devenish SO, et al. The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors[J]. Pharmacol Res, 2017, 119, 358- 370. doi: 10.1016/j.phrs.2017.02.022
20	Miller I, Scheffer IE, Gunning B, et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome: a randomized clinical trial[J]. JAMA Neurol, 2020, 77 (5): 613. doi: 10.1001/jamaneurol.2020.0073
21	Villanueva V, Laloyaux C, D'Souza W, et al. Effectiveness and tolerability of 12-month brivaracetam in the real world: EXPERIENCE, an international pooled analysis of individual patient records[J]. CNS Drugs, 2023, 37 (9): 819- 835. doi: 10.1007/s40263-023-01033-4
22	Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial[J]. The Lancet Neurol, 2020, 19 (1): 38- 48. doi: 10.1016/S1474-4422(19)30399-0
23	Chung SS, French JA, Kowalski J, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures [J/OL]. Neurology, 2020, 94(22) [2025-04-23]. https://www.neurology.org/doi/10.1212/WNL.0000000000009530.
24	Zhao W, Xie C, Zhang X, et al. Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy[J]. Brain Beh, 2023, 13 (6): e2995. doi: 10.1002/brb3.2995
25	Ravizza T, Scheper M, Di Sapia R, et al. mTOR and neuroinflammation in epilepsy: implications for disease progression and treatment[J]. Nat Rev Neurosci, 2024, 25 (5): 334- 350. doi: 10.1038/s41583-024-00805-1
26	Stockinger J, Strzelczyk A, Nemecek A, et al. Everolimus in adult tuberous sclerosis complex patients with epilepsy: Too late for success? A retrospective study[J]. Epilepsia, 2021, 62 (3): 785- 794. doi: 10.1111/epi.16829
27	Sourbron J, Lagae L. Fenfluramine: a plethora of mechanisms ?[J]. Front Pharmacol, 2023, 14, 1192022.
28	Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for treatment-resistant seizures in patients with dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial[J]. JAMA Neurol, 2020, 77 (3): 300. doi: 10.1001/jamaneurol.2019.4113
29	Kwan P, Brodie MJ. Early identification of refractory epilepsy[J]. New Engl J Med, 2000, 342 (5): 314- 319. doi: 10.1056/NEJM200002033420503
30	Nevitt SJ, Sudell M, Cividini S, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data [J/OL]. Cochrane Database Syst Rev, 2022, 2022(4) [2025-05-23]. http://doi.wiley.com/10.1002/14651858. CD011412.pub4.
31	Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial[J]. The Lancet, 2021, 397 (10282): 1363- 1374. doi: 10.1016/S0140-6736(21)00247-6
32	Kaye NS, Graham J, Roberts J, et al. Effect of open-label lamotrigine as monotherapy and adjunctive therapy on the self-assessed cognitive function scores of patients with bipolar I disorder[J]. J Clin Psychopharmacol, 2007, 27 (4): 387- 391. doi: 10.1097/JCP.0b013e3180a76dd2
33	Yan C, Liu J, Jiang J, et al. A non-inferiority randomized controlled study of Perampanel versus Oxcarbazepine monotherapy for post-stroke epilepsy[J]. Seizure, 2025, 125, 172- 178. doi: 10.1016/j.seizure.2025.01.016
34	Ma H, Zhu H, Chen F, et al. Efficacy and safety of perampanel monotherapy in Chinese patients with focal‐onset seizures: A single‐center, prospective, real‐world observational study[J]. Epilepsia Open, 2023, 8 (4): 1474- 1483. doi: 10.1002/epi4.12823
35	Terada K. Efficacy and tolerability of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed temporal lobe epilepsy: post hoc analysis of a randomized, double-blind trial[J]. Seizure, 2023, 112, 62- 67. doi: 10.1016/j.seizure.2023.09.011
36	Brigo F, Del Giovane C, Nardone R, et al. Intravenous antiepileptic drugs in adults with benzodiazepine-resistant convulsive status epilepticus: a systematic review and network meta-analysis[J]. Epil Beh, 2019, 101, 106466. doi: 10.1016/j.yebeh.2019.106466
37	Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial[J]. The Lancet, 2021, 397 (10282): 1375- 1386. doi: 10.1016/S0140-6736(21)00246-4
38	Bonnett LJ, Tudur Smith C, Donegan S, et al. Treatment outcome after failure of a first antiepileptic drug[J]. Neurology, 2014, 83 (6): 552- 560. doi: 10.1212/WNL.0000000000000673
39	Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on ?[J]. Seizure, 2000, 9 (7): 464- 468. doi: 10.1053/seiz.2000.0442
40	中华医学会神经病学分会中华医学会神经病学分会脑电图与癫痫学组. 抗癫痫发作药物联合使用中国专家共识[J]. 中华神经科杂志, 2024, 57 (2): 108- 117.
41	Sake JK, Hebert D, Isojärvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs[J]. CNS Drugs, 2010, 24 (12): 1055- 1068. doi: 10.2165/11587550-000000000-00000
42	Kowski AB, Schlabitz S, Steinbart D, et al. Adverse events of dual anti-seizure medication: real-life data from a tertiary epilepsy clinic[J]. Seizure, 2025, 126, 86- 94. doi: 10.1016/j.seizure.2025.01.022
43	Berry-Noronha A, Manoleehakul P, Rottler A, et al. Risk of adverse pregnancy outcomes associated with antiseizure medications and their indications: a systematic review and meta-analysis[J]. Neurology, 2025, 104 (3): e210233. doi: 10.1212/WNL.0000000000210233
44	Vajda F, O'Brien T, Graham J, et al. Specific fetal malformations following intrauterine exposure to antiseizure medication[J]. Epil Beh, 2023, 142, 109219. doi: 10.1016/j.yebeh.2023.109219
45	Battino D, Tomson T, Bonizzoni E, et al. Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry[J]. Epilepsia, 2013, 54 (9): 1621- 1627. doi: 10.1111/epi.12302
46	Vajda FJE, Hitchcock A, Graham J, et al. Seizure control in antiepileptic drug‐treated pregnancy[J]. Epilepsia, 2008, 49 (1): 172- 176. doi: 10.1111/j.1528-1167.2007.01412.x
47	Jiménez M, Grau-López L, Ciurans J, et al. Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy[J]. Neurología (English Edition), 2023, 38 (2): 106- 113. doi: 10.1016/j.nrleng.2020.04.029
48	中华医学会神经病学分会脑电图与癫痫学组. 中国围妊娠期女性癫痫患者管理指南[J]. 中华神经科杂志, 2021, 54 (6): 539- 544. doi: 10.3760/cma.j.cn113694-20201116-00879
49	中国抗癫痫协会护理专业委员会. 癫痫健康教育中国护理专家共识_中国抗癫痫协会护理专业委员会 [J]. 癫痫杂志, 2024, 10(6): 495-502.
50	Tomson T, Battino D, Bromley R, et al. Executive summary: management of epilepsy in pregnancy: a report from the international league against epilepsy task force on women and pregnancy[J]. Epilepsia, 2019, 60 (12): 2343- 2345. doi: 10.1111/epi.16395
51	Alvarez I, Tötterman K, Honkaniemi E, et al. Breastfed infants exposed to lamotrigine faced a low risk of toxic effects[J]. Acta Paediatrica, 2025, 114 (2): 346- 354. doi: 10.1111/apa.17432
52	Hope OA, Harris KM. Management of epilepsy during pregnancy and lactation [J]. BMJ, 2023: e074630.
53	Mahmoudian T, Iranpour R, Messri N. Serum lipid levels during carbamazepine therapy in epileptic children[J]. Epil Beh, 2005, 6 (2): 257- 259. doi: 10.1016/j.yebeh.2004.11.013
54	Mintzer S, Dimova S, Zhang Y, et al. Effects of lacosamide and carbamazepine on lipids in a randomized trial[J]. Epilepsia, 2020, 61 (12): 2696- 2704. doi: 10.1111/epi.16745
55	Mintzer S, Skidmore CT, Abidin CJ, et al. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein[J]. Ann Neurol, 2009, 65 (4): 448- 456. doi: 10.1002/ana.21615
56	Martin RC, Griffith HR, Faught E, et al. Cognitive functioning in community dwelling older adults with chronic partial epilepsy[J]. Epilepsia, 2005, 46 (2): 298- 303. doi: 10.1111/j.0013-9580.2005.02104.x
57	Vary-O'Neal A, Miranzadeh S, Husein N, et al. Association between frailty and antiseizure medication tolerability in older adults with epilepsy [J/OL]. Neurology, 2023, 100(11) [2025-05-04]. https://www.neurology.org/doi/10.1212/ WNL.0000000000201701.

ASMs	Seizure type	Mechanism	Common adverse effects	Effects on hepatic enzymes
First generation
PHB	FOS and GTCS	Increases GABA levels	Fatigue, somnolence, depression, impaired attention, hyperactivity, irritability, aggressive behavior, memory impairment	Inducer
PHT	FOS, GTCS (may worsen myoclonic seizures)	Sodium channel blocker	Nystagmus, ataxia, anorexia, nausea, vomiting, aggressive behavior, megaloblastic anemia	Inducer (CYP1A2, CYP3A, CYP2C9, CYP2C19, PGP, UGT)
CZP	Myoclonic-atonic seizures	Enhances GABA_A mediated inhibition	Sedation, ataxia, irritability, occasional leukopenia	-
CBZ	FOS, GTCS (may worsen myoclonic seizures)	Sodium channel blocker	Diplopia, dizziness, nausea, drowsiness, hyponatremia, neutropenia, osteoporosis	Inducer (CYP1A2, CYP3A, CYP2C9, CYP2C19, PGP, UGT)
VPA	FOS, GTCS, absence seizures, myoclonic seizures	Sodium channel blocker, enhances GABA, T-type calcium channel blocker	Nausea, vomiting, drowsiness, tremor, thrombocytopenia/neutropenia, weight gain, osteoporosis, pancreatitis	Inhibitor (CYP2C9, epoxide hydrolase, UGT)
Second generation
GBP	FOS (may worsen myoclonic seizures)	P/Q-type calcium channel blocker	Somnolence, dizziness, ataxia, fatigue, weight gain, peripheral edema	-
LTG	FOS, GTCS (may worsen myoclonic seizures)	Sodium channel blocker, may increase GABA levels	Headache, blurred vision, diplopia, instability, insomnia, tremor, rash	Inducer (UGT) Inhibitor (UGT, CYP2C19)
TPM	FOS, GTCS	Sodium channel blocker, may enhance GABA activity, AMPA receptor antagonist	Sedation, fatigue, dizziness, ataxia, depression, weight loss, memory impairment, word-finding difficulties, kidney stones	Weak inducer (CYP3A4) Weak inhibitor (CYP2C19)
LEV	FOS, GTCS, myoclonic seizures	Binds to SV2A protein	Somnolence, dizziness, weakness, irritability	-
OXC	FOS, GTCS (may worsen myoclonic seizures)	Sodium channel blocker	Drowsiness, headache, fatigue, hyponatremia, osteoporosis	Weak inducer (CYP3A4) Weak inhibitor (CYP2C19)
ZNS	FOS, Generalized seizures, myoclonic seizures	Blocks sodium and calcium channels, weak carbonic anhydrase inhibitor	Psychiatric symptoms, memory impairment, word-finding difficulties, kidney stones	-
Third generation
LCM	FOS, GTCS	Slow sodium channel inactivation	Dizziness, somnolence, nausea, diplopia, cardiac arrhythmias	-
PER	FOS, GTCS	AMPA receptor antagonist	Dizziness, somnolence, nausea, falls	Weak inhibitor/inducer (CYP3A4)
ESL	FOS	Blocks sodium channels, stabilizes the inactive state of voltage-gated sodium channels	Dizziness, somnolence, headache, diplopia, nausea, ataxia	Weak inhibitor (CYP2C19) Weak inducer (CYP3A4)
BRV	FOS	Binds to SV2A	Somnolence, dizziness, fatigue, irritability	-

ASMs	Seizure type	Mechanism	Common adverse effects	Effects on hepatic enzymes
First generation
PHB	FOS and GTCS	Increases GABA levels	Fatigue, somnolence, depression, impaired attention, hyperactivity, irritability, aggressive behavior, memory impairment	Inducer
PHT	FOS, GTCS (may worsen myoclonic seizures)	Sodium channel blocker	Nystagmus, ataxia, anorexia, nausea, vomiting, aggressive behavior, megaloblastic anemia	Inducer (CYP1A2, CYP3A, CYP2C9, CYP2C19, PGP, UGT)
CZP	Myoclonic-atonic seizures	Enhances GABA_A mediated inhibition	Sedation, ataxia, irritability, occasional leukopenia	-
CBZ	FOS, GTCS (may worsen myoclonic seizures)	Sodium channel blocker	Diplopia, dizziness, nausea, drowsiness, hyponatremia, neutropenia, osteoporosis	Inducer (CYP1A2, CYP3A, CYP2C9, CYP2C19, PGP, UGT)
VPA	FOS, GTCS, absence seizures, myoclonic seizures	Sodium channel blocker, enhances GABA, T-type calcium channel blocker	Nausea, vomiting, drowsiness, tremor, thrombocytopenia/neutropenia, weight gain, osteoporosis, pancreatitis	Inhibitor (CYP2C9, epoxide hydrolase, UGT)
Second generation
GBP	FOS (may worsen myoclonic seizures)	P/Q-type calcium channel blocker	Somnolence, dizziness, ataxia, fatigue, weight gain, peripheral edema	-
LTG	FOS, GTCS (may worsen myoclonic seizures)	Sodium channel blocker, may increase GABA levels	Headache, blurred vision, diplopia, instability, insomnia, tremor, rash	Inducer (UGT) Inhibitor (UGT, CYP2C19)
TPM	FOS, GTCS	Sodium channel blocker, may enhance GABA activity, AMPA receptor antagonist	Sedation, fatigue, dizziness, ataxia, depression, weight loss, memory impairment, word-finding difficulties, kidney stones	Weak inducer (CYP3A4) Weak inhibitor (CYP2C19)
LEV	FOS, GTCS, myoclonic seizures	Binds to SV2A protein	Somnolence, dizziness, weakness, irritability	-
OXC	FOS, GTCS (may worsen myoclonic seizures)	Sodium channel blocker	Drowsiness, headache, fatigue, hyponatremia, osteoporosis	Weak inducer (CYP3A4) Weak inhibitor (CYP2C19)
ZNS	FOS, Generalized seizures, myoclonic seizures	Blocks sodium and calcium channels, weak carbonic anhydrase inhibitor	Psychiatric symptoms, memory impairment, word-finding difficulties, kidney stones	-
Third generation
LCM	FOS, GTCS	Slow sodium channel inactivation	Dizziness, somnolence, nausea, diplopia, cardiac arrhythmias	-
PER	FOS, GTCS	AMPA receptor antagonist	Dizziness, somnolence, nausea, falls	Weak inhibitor/inducer (CYP3A4)
ESL	FOS	Blocks sodium channels, stabilizes the inactive state of voltage-gated sodium channels	Dizziness, somnolence, headache, diplopia, nausea, ataxia	Weak inhibitor (CYP2C19) Weak inducer (CYP3A4)
BRV	FOS	Binds to SV2A	Somnolence, dizziness, fatigue, irritability	-

[1]	王天爽, 王新华, 周渊峰. 儿童癫痫综合征药物治疗进展[J]. 中国临床药理学与治疗学, 2026, 31(2): 154-161.
[2]	赵正卿, 李雁鹏, 赵忠新. 女性癫痫患者的临床特点和药物治疗研究进展[J]. 中国临床药理学与治疗学, 2026, 31(2): 162-167.
[3]	翟菲菲, 黄颜. 睡眠相关过度运动性癫痫诊疗进展[J]. 中国临床药理学与治疗学, 2026, 31(2): 168-174.
[4]	曲悠扬, 朱雨岚. 癫痫持续状态诊断与治疗研究现状[J]. 中国临床药理学与治疗学, 2026, 31(2): 175-184.
[5]	施雅妍, 王钰, 旷炜, 余守洋. 多发性硬化的发病机制和药物治疗的最新进展[J]. 中国临床药理学与治疗学, 2026, 31(1): 78-87.
[6]	刘醒, 陈颖. 2型糖尿病的药物治疗及新技术进展[J]. 中国临床药理学与治疗学, 2025, 30(9): 1215-1223.
[7]	赵亚红, 李强. 靶向铁死亡与癫痫治疗研究进展[J]. 中国临床药理学与治疗学, 2025, 30(6): 828-834.
[8]	周明骏, 桑雪, 常静雯, 刘芳, 陶羽, 范方田. 阳离子失衡参与继发性脊髓损伤的机制及潜在干预药物的研究进展[J]. 中国临床药理学与治疗学, 2025, 30(11): 1559-1568.
[9]	徐秋郁, 艾三喜, 王淦淦, 贾淳钰, 王佳慧, 郑可, 秦岩, 陈罡, 李雪梅. 小剂量利妥昔单抗改善早期中高风险膜性肾病疾病进展：一项探索性研究[J]. 中国临床药理学与治疗学, 2024, 29(7): 744-751.
[10]	黄春芝, 刘青蓝, 苏冉, 孙楠. 青少年子宫内膜异位症药物治疗选择及药物治疗进展[J]. 中国临床药理学与治疗学, 2024, 29(5): 535-542.
[11]	陈思蕊, 李军强, 党小利, 王天成. 吡仑帕奈在癫痫共病治疗中的研究进展[J]. 中国临床药理学与治疗学, 2024, 29(3): 354-360.
[12]	武兴东, 岳红梅, 朱浩斌, 刘苗苗, 李雅亭, 许金回. 药物治疗阻塞性睡眠呼吸暂停的研究进展[J]. 中国临床药理学与治疗学, 2024, 29(2): 215-229.
[13]	赵全铭, 杨满斗, 胡义波, 苏有橦, 普丽, 章瑜, 李文亮. 胃肠道间质瘤药物治疗和耐药机制研究进展[J]. 中国临床药理学与治疗学, 2024, 29(1): 82-89.
[14]	王娟, 刘维英, 叶育才, 付文丽, 张莎, 李乐萍. 去甲肾上腺素再摄取抑制剂联合抗毒蕈碱剂治疗阻塞性睡眠呼吸暂停的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 714-720.
[15]	俞亚红, 宋昱. 左心室辅助装置植入患者的药物治疗[J]. 中国临床药理学与治疗学, 2023, 28(2): 198-204.